<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809935</url>
  </required_header>
  <id_info>
    <org_study_id>204610401</org_study_id>
    <nct_id>NCT04809935</nct_id>
  </id_info>
  <brief_title>EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy</brief_title>
  <official_title>Endoscopic Ultrasound Guided Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Intractable Pain Due to Malignancy A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many cancer patients suffer from intractable pain and which is often suboptimally controlled&#xD;
      by even strong opioid analgesics. Coeliac plexus neurolysis (CPN) is procedure which intended&#xD;
      to permanently destroy the nociceptive pathway that transmits the pain caused by the tumour.&#xD;
      It can be with different approaches, such as percutaneously guided by fluoroscopy,&#xD;
      echo-endoscopically or surgically with endoscopic approach being the more popular one in many&#xD;
      centers equipped with echo-endoscopic services. The effect of CPN has been well established&#xD;
      by some retrospective series. The overall response rate to CPN ranges from 70-90%, however,&#xD;
      the analgesic effect is limited and up to roughly around 3 months. It is believed that the&#xD;
      short-lasting analgesic effect is related to incomplete neurolysis by absolute alcohol&#xD;
      injection.&#xD;
&#xD;
      Recently, radiofrequency ablation (RFA) of coeliac plexus has been introduced as another mode&#xD;
      of CPN. So far, only one small single center randomized controlled trial (RCT) suggesting&#xD;
      superior performance in favour to CPN using RFA. This result has to be validated and by a RCT&#xD;
      with larger sample size. In addition, data concerning the quality of life (QOL) improvement&#xD;
      and cost-effectiveness need to be further elucidated. Therefore, the aim of this study is to&#xD;
      perform a RCT to look into these issues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare the efficacy of EUS-guided CPN versus radiofrequency&#xD;
      ablation in patients with pain related to pancreatic cancer. By performing a randomized&#xD;
      controlled trial, the clinical outcomes and cost-effectiveness of this new RFA treatment&#xD;
      approach can be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pain score at 4 weeks after procedure (by VAS score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks</time_frame>
    <description>Technical success rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate</measure>
    <time_frame>2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks</time_frame>
    <description>Decrease of pain level by 30% from pre-procedural baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of procedure</measure>
    <time_frame>Up to 1 hour</time_frame>
    <description>Time from injection of pre-medication to procedure last observation recording at the procedure suite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain score drop by 50%</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>Time to Visual Analog Score drop by 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short term complication rate</measure>
    <time_frame>Up to 1 week</time_frame>
    <description>Complication rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term complication rate</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>Complication rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Up to 100 months</time_frame>
    <description>Hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status (Quality of life)</measure>
    <time_frame>2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks</time_frame>
    <description>The Short Form (36) Health Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) in patients with pancreatic cancer</measure>
    <time_frame>2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks</time_frame>
    <description>PAN-26 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) of cancer patients</measure>
    <time_frame>2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks</time_frame>
    <description>QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of two types approach</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>Total cost ($) of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Cancer of Pancreas</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Pain</condition>
  <condition>Cancer-Associated Pain</condition>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>EUS-CPB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemical ablation of the coeliac plexus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS-CPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiofrequency ablation of the coeliac plexus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>98% dehydrated alcohol</intervention_name>
    <description>coeliac plexus is identified and punctured&#xD;
Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol.</description>
    <arm_group_label>EUS-CPB</arm_group_label>
    <other_name>Chemical Ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>19G EUSRA needle, Taewoong Medical, Korea</intervention_name>
    <description>10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s&#xD;
Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan</description>
    <arm_group_label>EUS-CPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 year-old&#xD;
&#xD;
          -  Patients who give informed consent to the study&#xD;
&#xD;
          -  Suboptimal pain control with regular analgesics&#xD;
&#xD;
          -  Inoperable cancer of pancreas&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to give consent&#xD;
&#xD;
          -  Patients aged &lt;18 years&#xD;
&#xD;
          -  EUS not possible due to:&#xD;
&#xD;
        Problem related to scope insertion such as trismus, stenosis of the upper GI tract&#xD;
        Coagulopathy with INR &gt;1.5 or platelet count &lt; 70&#xD;
&#xD;
          -  Low oxygen saturation or extreme blood pressure render endoscopic procedure unsafe&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ka Wing Ma, MBBS, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wan Yee Chiu, BISC</last_name>
    <phone>+852 2255 4848</phone>
    <email>krissy23@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>000000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan Yee Chiu, BISC</last_name>
      <phone>+852 2255 4848</phone>
      <email>krissy23@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Ka Wing Ma, MBBS, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Ma Ka Wing</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Endoscopic Ultrasound Guided</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>Coeliac plexus neurolysis</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Pain Relief</keyword>
  <keyword>Chemical coeliac plexus neurolysis</keyword>
  <keyword>Coeliac plexus ablation</keyword>
  <keyword>Cancer pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

